Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis

Arcutis Biotherapeutics has moved from a clinical-stage biotech to a commercial dermatology company built around ZORYVE, a once-daily non-steroidal PDE4 inhibitor available in cream and foam formulations. ZORYVE targets chronic plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with a U.S. TAM of 30 million diagnosed patients and a large conversion opportunity because corticosteroids account for more than 69% of topical prescriptions. **Commercial momentum is accelerating:** Q2 2026 net product sales reached $129.9 million, up 59% year over year and 23% sequentially, beating the $118.47 million consensus estimate by approximately 9.7%. Management raised 2026 sales guidance to $525 million-$540 million, implying a midpoint of $532.5 million. **Profitability has inflected:** the company delivered its first GAAP net income of $15.0 million, or $0.11 per diluted share, generated $12.6 million of operating cash flow, and achieved an approximately 91% gross margin. At an enterprise value of approximately $3.2 billion, the stock trades at 6.0x forward sales on the 2026 midpoint. Near-term catalysts include the primary-care and pediatric sales-force launch and the February 23, 2027 FDA action date for infant atopic dermatitis; longer-term value depends on converting steroid volume and extending the franchise beyond dermatology.